Purpose: To assess the follow-up and response to treatment in patients with RAP.
INTRODUCTION
Retinal angiomatous proliferation (RAP) has recently been described and systematized (1) as a clinical variant of Age Related Macular Degeneration (ARMD). Technical improvements such as dynamic ICG or OCT (2) have facilitated a more detailed knowledge of the anatomic and functional characteristics of this pathology, which comprise the appearance of a retinal angiomatous lesion or a intra-retinal neovascularization rapidly progressing toward the subretinal space (usually associated to a serous detachment of the pigmentary epithelium), and concludes with the appearance of choroidal neovascularization with which it merges through thick retino-choroidal communication paths (3) .
In general, RAP has a negative prognosis and it frequently becomes bilateral (some series even reach 100% after 3 years) (4) . Different treatments have been utilized, on their own or associated, to handle this disease, including photodynamic therapy (PDT), trans-pupillary thermal therapy (TTT), direct argon laser photocoagulation, antiangiogenic medication and intravitreous corticoids, and even surgery (5-7). However, said series are small and the handling thereof is not yet standardized.
In our center, various treatments have been utilized for managing RAP relapses or episodes. This paper aims at reviewing said treatments, focusing on their effectiveness and outlining their complications while taking into account the limitations of a retrospective study in a small series.
MATERIAL AND METHODS
A retrospective study of patients with a diagnosis of RAP who were attended in our service between march 2002 and August 2005. the retrospective nature of the study resulted in the exclusion of some patients due to lack of follow-up or incomplete data. The analysis was restricted to patients with adequate follow-up and who regularly complied with the check-ups.
The inclusion criteria for the RAP diagnostic were the associated of intraretinal angiomatous lesion in: -An age of 55 or above. (TFD+FD+TIV). Conclusiones: A pesar del mal pronostico final de la RAP, el tratamiento más eficaz en cada brote fue la asociación de terapia fotodinámica, fotocoagulación focal y triamcinolona intravítrea. Mientras que el peor fue la TTT.
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ried out, comprising visual acuity with standard Snellen optotypes, anterior pole assessment with slit lamp, intraocular pressure and eye fundus exploration with Goldman or Volk Superfield NC lens.
After suspicion and in a time period under 15 days from the first exploration, the following were carried out: dynamic retinal angiography with fluorescein and indocyanine green (HRA Engineering, Heidelberg) and OCT (OCT 3, Zeiss), classified in the 3 stages of the Yannuzzi classification.
The treatment was carried out the same day, with the ophthalmologist utilizing treatment techniques on the basis of the clinical findings and the most useful technique in the light of the knowledge at the time.
The following therapies have been analyzed, in isolated or combined utilization: -Photodynamic therapy with verteporfin, following the standard recommendations, although it was carried out after the exploration taking advantage of the peripheral venous path utilized for administering the dyes. The laser source was the Activis equipment of Quantel Medical (Quantel Medical Inc, Clermont-Ferrand, France)-BVI which emits a red laser 689 nm beam. When combined with direct photocoagulation, the PDT was performed first and then the green argon laser was applied (frequency 532 nm, divided laser Nd:YAG). When combined with intravitreous triamcinolone, it was administered between 3 and 5 days after PDT. -Transpupillary thermal therapy was administered with the Iris Medical equipment (Iris Medical Instruments, Mountain View, CA, USA), which utilizes a diode source (810 nm) with a sub-threshold technique with Mainster de Volk lens (broad field if 125°), utilizing the table recommended by the manufacturer. The administration time was fixed at 1 minute and, when a 3 mm outlet diameter was utilized (true diameter 4.41 mm) the power was of 1094 mW and, when utilizing the 2 mm outlet (true diameter 2.94 mm) the power was of 729 mW. -Intravitreous triamcinolone. Three days before and after chloramphenicol eye drops were administered at 8 hour intervals. In a specific room, separated from the surgery area and after topical anesthesia and single dosage Betadine ® drops [10% iodine povidona diluted at 50%, blepharostate was applied using sterile gloves, and 0,1 ml (4 mgrs) of Triamcinolone (Trigon depot ® ), were injected without prior manipulation. The patient remained under observation until the pain remitted (if any) or the vision recovered. The IOP was controlled as well as the existence of adverse effects one week later. -Direct photocoagulation, administered with a green argon laser (frequency 532 nm, split laser Nd:YAG), starting with a size of 100 µ and an intensity of 100 mW and exposure time of 111 msec, increasing the intensity and exposure parameters until the whitening of the superficial vascular lesion.
In one patient we utilized direct photocoagulation with infrared laser enhanced with indocyanine green plus intravitreous triamcinolone, during one of the episodes.
The patient was followed up one week later, when triamcinolone was injected, in the remaining patients the follow-up was at one month for the first 3 months and then at 3-month intervals until month 12. If a relapse or new lesion appeared, the cycle was repeated.
The results have been summarized in an Excel table of the Office XP software (Microsoft Excel, Microsoft Co, USA), making a descriptive study of the qualitative and quantitative variables.
The visual acuity was assessed in 5 ranges of vision: under 0,05, between 0.05 and 0.1 between 0.2 and 0.3, between 0.4 and 0.5, and equal to or above 0.6, interpreting an improvement or deterioration as a jump from one range to another in either direction. The best visual acuity after treatment was utilized to assess the effectiveness of the therapeutic technique. Patients were followed up until obtaining atrophic or dry lesions or the therapeutic possibilities were deemed to be exhausted or they remained in observation, with a minimum followup of 3 months.
RESULTS
The tables show the results of 15 eyes in 14 patients. The epidemiological and initial assessment data are in Table I . The mean age is of 77.5 (SD 6,7) years. Table II shows the initial VA, the final VA after treatment and the vision and pathology of the contralateral eye.
Adding up all the treated episodes we had: nine in stage 1, 17 in stage 2 and 12 in stage 3. Photodynamic therapy was utilized in 18 episodes: five in isolation, three associated to direct photocoagula-tion, five associated to intravitreous triamcinolone and five with intravitreous triamcinolone plus direct photocoagulation. The results are shown in Table III .
As the patients were submitted to different therapeutic techniques during their episodes, these were assessed separately to evaluate the efficiency of the technique.
The development stage of the lesions in the first treatment were: seven in stage 1 and eight in stage 2. As the number of episodes increased, the more advanced stages also increased. In total and adding all the treated episodes we had nine in stage 1, seventeen in stage 2 and twelve in stage 3.
Photodynamic therapy was utilized in 18 stages: 5 in isolation, 3 associated to direct photocoagulation, 5 associated to intravitreous triamcinolone and 5 with intravitreous triamcinolone and direct photocoagulation. The results are shown in Table III .
Transpupillary thermal therapy was performed in 14 episodes in isolation, and in two associated to intravitreous triamcinolone. The results are in Table  IV In one case the single treatment for an episode was intravitreous triamcinolone, direct photocoagulation plus intravitreous triamcinolone, direct photocoagulation in afferent vessel with diode enhanced with indocyanine green plus intravitreous triamcinolone, and only direct photocoagulation. The results of the utilized techniques were analyzed only if they were used on 5 occasions.
Assessment of the best VA after treatment: -Photodynamic therapy: improvement in one case, stable in one and worsening in 3.
-Photodynamic therapy and intravitreous triamcinolone: improvement in 2, stable in 2 and worsening in 1.
-Photodynamic therapy with intravitreous triamcinolone and direct photocoagulation: improvement in 3 and stable in 2.
-Transpupillary thermal therapy: improvement in 2, stable in 11 and worsening in 1 case.
Of the 14 patients of the series, intravitreous triamcinolone was utilized in 7 (eyes), one patient rejected its use and another one could not use it due to glaucoma. The following complications were analyzed:
Fifteen intravitreous were placed in the 7 eyes (in two cases 1, in two cases 2 and in three cases 4), without the emergence of endophthalmitis.
In 3 eyes (42.8%) a cortisone glaucoma emerged, which was controlled with medical treatment.
Finally, two eyes were pseudophakic and 5 phakic, of which at the end of the follow-up cataract surgery was prescribed for two patients, who rejected it due to the negative visual prognosis, and in another the cataracts evolved.
DISCUSSION
RAP is a clinical variant of ARMD which has been described and analyzed only recently (1) . With increasing frequency we must face this problem in our daily clinical practice. However, there are very few publications standardizing the management of this pathology.
RAP is characterized by the emergence of a juxta-or extrafoveal intraretinal vascular proliferation, with a large edematous-exudative component, which is accompanied in 75-80% of cases by an underlying serous pigmentary epithelium detachment (SPED) and in 30% of cases it is also accompanied by an adjacent neuroepithelium serous detachment (ANSD) (2, 3) .
In spite of the juxta-or extrafoveal origin, it is characterized by a negative prognosis (1,3,7) . In our series it can be seen how, at the end of the follow- TTT3  FC 1/2 m  2  0,2  TTT1  0,3  2  0,3  TTT2  0,2  3  0,1  TTT3 + IVT1  0,2  2  0,1  TTT1 + IVT1  0,2 up, 80% of eyes remain with a VA below 0,1 and there is a loss of vision compared with the initial VA. Taking into account that the mean follow-up has been of 15.9 months (SD 9.5) and the mean treatment time of 2.5 (SD 1.7), the functional results vis-à-vis the resources utilized for their management have been disappointing: 46% had deteriorated eyesight, el 46.7% remained stable and only 6.6% improved. An additional characteristic is the high bilateralization frequency: compared to 43% of bilateralization in all ARMD groups (8), RAP becomes bilateral in 40% during year 1.52% during year 2 and 100% during year 3 (3). 65% of our patients had advanced humid ARMD or RAP in the contralateral eye, this being the cause why most of the contralateral eyes also had a VA under 0.1 ( fig. 1) .
Multiple surgical and medical treatments have been utilized for wet ARMD. For RAP, in isolated patients, the afferent and efferent vessels of the intra-retinal neovascularization were sectioned (6). However, the multiple and relapsing nature of this disease does not point at surgery as a logical option, although it might be indicated in some cases.
Photodynamic therapy has also been utilized in RAP in a 13-case series by Boscia (9) obtaining occlusion of the lesion and flattening of the DSEP in 3 cases (23%) with pigmentary epithelium rupture in 3 cases with large DSEP. A similar result was obtained by Bottoni (5) , where only 11% (in stage 2) were deactivated. In our series (Table III) , PDT was utilized in 5 cases (all in stage 2) and only one exhibited eyesight improvement and in another case it stabilized. PDT on its own is not a very efficient treatment for this pathology because, due to its action mechanism, it is useful in neovessels of choroidal origin, particularly its classical expression. However, in the first stages of this pathology the neovascular lesion is purely intra-retinal.
Transpupillary thermal therapy has the advantage of maintaining the fiber layer and has better penetration through the subretinal hemorrhages (10), taking into account that 94% of RAP associate retinal hemorrhage (3) and considering the paper by Gass stating that these cases always included a hidden membrane (11) . We applied this technique in the first cases. It was utilized in 3 episodes, in isolation, and only two cases exhibited vision improvement (14%). Bottoni had only 5 cases in his series (5) and achieved obliteration in two (in stage 2) and, although in our series we only assess visual acuity, non of the seven stage 2 cases we treated exhibited improvements. In general, TTT is not a technique indicated for RAP and Gass' ideas and classification could not be confirmed.
Argon laser has proved to be the most efficient technique in stage 1, with 73% of obliterations. However, in stage 2 the rate is reduced to 17% regardless of the fact that the early treatment of the disease (figs. Intravitreous triamcinolone (IVT) was utilized in the treatment of ARMD due to its ability to repair the internal hemato-retinal barrier and its antiangiogenic properties (12, 13) , which leads to an improvement of the associated cystic macular edema and reduces the membrane size and number of subsequent treatments when associated to PDT. As a simple doses lasts 3-4 months its combined utilization is recommended (14) . In our series it has been utilized in isolation and combined with TTT, PDT and PDT plus direct photocoagulation. The main drawback were complications: in our series, we had no endophthalmitis in the 15 intraocular injections, however out of the 7 eyes in which they were utilized three had high IOP which was controlled with medical treatment (42.8%). This percentage is similar to that of other ARMD series such as that of Jonas (13) Finally, cataracts (which are an important complication in other indications) is not very important in senility because some cases are already pseudophakic or surgery at this age is easily accepted. Surgery was indicated in 2 of our 5 phakic patients and in another one the existing cataract evolved.
The best results were provided by combined treatments. We can only describe two associations because these were made in at least 5 occasions: the associated of PDT plus IVT was utilized in stage 2 and 3 episodes, achieving VA improvements in two. The association of PDT plus IVT plus direct photocoagulation produced the best results of all. It was utilized in stages 1 and 3 and, although it is true that the best results are obtained in early stages (5), the difference is large, in 4 of the 5 treatments the eyesight improved. Even though the initial VAs are better in this group, this should not exert influence and the comparison is valid because in the global analysis of the series ( fig. 7) , the more visual acuity they have, the more they lose. Maybe only direct photocoagulation and the intravitreous Trigon were enough in stage 1, we did not analyze this, but the association with photodynamic therapy was the most efficient technique of all those utilized.
Probably said techniques act in a different and synergystic manner: direct photocoagulation obliterates due to its thermal effect the intraretinal neovascularization, while photodynamic therapy can act on the intraretinal and/or subretinal (if any) component as well as on the choroids, contributing to resolve the pigmentary epithelium detachment, and finally triamcinolone would act as an antiangiogenic and reducing the peri-lesional exudation which is so important in RAP.
In the absence of experience with the new intravitreous or peribulbar antiVEGF, the association of PDF plus IVT plus direct photocoagulation is the most useful one for managing RAP in stages 1 and 2. In contrast, the least efficient technique is TTT in any of the 3 stages.
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Fig. 7: Global results according to the initial vision.
The eyes which start with better eyesight are those which lose more.
